A Phase 2 interventional study of GB002 (seralutinib) and Placebo in Pulmonary Artery Hypertension, sponsored by GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.. Completed at 63 sites in 11 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-11-07.
Sponsored by GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objective for this trial is to determine the effect of GB002 (seralutinib) on improving pulmonary hemodynamics in subjects with World Health Organization (WHO) Group 1 PAH who are Functional Class (FC) II and III. The secondary objective for this trial is to determine the effect of GB002 (seralutinib) on improving exercise capacity in this population.
GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. is the lead sponsor of 3 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
A current diagnosis of symptomatic PAH classified by one of the following:
Documentation of cardiac catheterization within the screening period that is consistent with the diagnosis of PAH and meeting all the following criteria, to be confirmed by a central hemodynamic core laboratory:
Pulmonary function tests (PFTs) at screening with the following criteria met:
Exclusion Criteria:
NOTE: Additional inclusion/exclusion criteria may apply, per protocol.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GB002 (seralutinib) inhaled orally twice per day (BID) for 24 weeks
Drug: GB002 (seralutinib) · Device: Generic Dry Powder Inhaler
Placebo inhaled orally BID for 24 weeks
Drug: Placebo · Device: Generic Dry Powder Inhaler
Capsule containing GB002 (seralutinib)
Matching capsule containing placebo
Generic dry powder inhaler for GB002 (seralutinib) or placebo delivery
Change From Baseline to Week 24 in Pulmonary Vascular Resistance (PVR)
PVR was evaluated using right heart catheterization (RHC).
Time frame: Baseline, Week 24
Change From Baseline to Week 24 in Distance Achieved on the Six-Minute Walk Test (6MWT)
The 6MWT measures the distance a participant is able to walk quickly on a flat, hard surface in a period of 6 minutes.
Time frame: Baseline, Week 24
| Milestone | Placebo | GB002 (Seralutinib) |
|---|---|---|
| Started | 42 | 44 |
| Completed | 42 | 38 |
| Not completed | 0 | 6 |
| Withdrew: Adverse event | 0 | 4 |
| Withdrew: Protocol deviation | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 1 |
PVR was evaluated using right heart catheterization (RHC).
| dyne•s/cm^5 | Placebo | GB002 (Seralutinib) |
|---|---|---|
| Change From Baseline to Week 24 in Pulmonary Vascular Resistance (PVR) | 21.2 (-37.4 to 79.8) | -74.9 (-139.7 to -10.2) |
The 6MWT measures the distance a participant is able to walk quickly on a flat, hard surface in a period of 6 minutes.
| meters | Placebo | GB002 (Seralutinib) |
|---|---|---|
| Change From Baseline to Week 24 in Distance Achieved on the Six-Minute Walk Test (6MWT) | 7.4 (-11.2 to 25.9) | 13.9 (-5.1 to 32.8) |
Collected over From first dose of study drug through Week 28. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/42 (0%) | 6/42 (14.3%) | 28/42 (66.7%) |
| GB002 (Seralutinib) | 0/44 (0%) | 10/44 (22.7%) | 31/44 (70.5%) |
| Event | Placebo | GB002 (Seralutinib) |
|---|---|---|
| Right ventricular failureCardiac disorders | 3/42 | 1/44 |
| HypokalaemiaMetabolism and nutrition disorders | 1/42 | 0/44 |
| Pericardial effusionCardiac disorders | 1/42 | 0/44 |
| Orthostatic hypotensionVascular disorders | 1/42 | 0/44 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 1/42 | 0/44 |
| AppendicitisInfections and infestations | 0/42 | 1/44 |
| PneumoniaInfections and infestations | 0/42 | 1/44 |
| Staphylococcal bacteraemiaInfections and infestations | 0/42 | 1/44 |
| Vascular device infectionInfections and infestations | 0/42 | 1/44 |
| LymphomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/42 | 1/44 |
| Event | Placebo | GB002 (Seralutinib) |
|---|---|---|
| CoughRespiratory, thoracic and mediastinal disorders | 16/42 | 19/44 |
| HeadacheNervous system disorders | 8/42 | 6/44 |
| COVID-19Infections and infestations | 7/42 | 6/44 |
| NauseaGastrointestinal disorders | 6/42 | 5/44 |
| DiarrhoeaGastrointestinal disorders | 3/42 | 6/44 |
| DizzinessNervous system disorders | 2/42 | 5/44 |
| FatigueGeneral disorders | 3/42 | 5/44 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 4/42 | 4/44 |
| NightmarePsychiatric disorders | 1/42 | 4/44 |
| Upper respiratory tract infectionInfections and infestations | 3/42 | 1/44 |
| Age, Continuous(years) | Placebo | GB002 (Seralutinib) | Total |
|---|---|---|---|
| Mean | 49.5 ± 11.81 | 48.3 ± 12.70 | 48.8 ± 12.22 |
| Sex: Female, Male(Participants) | Placebo | GB002 (Seralutinib) | Total |
|---|---|---|---|
| Female | 38 | 40 | 78 |
| Male | 4 | 4 | 8 |
| Race/Ethnicity, Customized(Participants) | Placebo | GB002 (Seralutinib) | Total |
|---|---|---|---|
| White | 37 | 37 | 74 |
| Black or African American | 1 | 0 | 1 |
| Asian | 2 | 4 | 6 |
| Other, Not Specified | 2 | 3 | 5 |
| Race/Ethnicity, Customized(Participants) | Placebo | GB002 (Seralutinib) | Total |
|---|---|---|---|
| Hispanic or Latino | 6 | 8 | 14 |
| Not Hispanic or Latino | 34 | 36 | 70 |
| Not Reported | 2 | 0 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Nov 2020 to primary completion in Oct 2022, 23 months.
Results were first posted in Nov 2023, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Seralutinib
Familial Primary Pulmonary Hypertension
GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.